Reference

Antitumor sustained-release injection containing bendamustine and its synergistic agent taxanes and plant alkaloids

All Rights Reserved. Antitumor sustained-release injection containing bendamustine and its synergistic agent taxanes and plant alkaloids. Gao, Hualan (Jinan Shuaihua Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China). Faming Zhuanli Shenqing Gongkai Shuomingshu CN 1887269 A 3 Jan 2007, 22pp. (Chinese). (People's Republic of China). CODEN: CNXXEV. APPLICATION: CN 2010-200735 25 Jul 2006. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 The title injection is composed of sustained-release microsphere comprising biol. effective constituents of bendamustine and its synergistic agent taxanes and plant alkaloids 0.5-60%, sustained-release adjuvant 40-99%, and suspending agent 0.0-30%, and solvents. The suspending agent is one of sodium CM-cellulose, sorbitol, tween, etc., or their combination thereof. The adjuvant is selected from one of polylactic acid, ethylene-vinyl acetate copolymer, racemic polylactic acid, etc., or their mixt. thereof.In this experiment, several chemicals are used like 9006-65-9 and 162652-95-1 The taxanes are selected from taxol, docetaxel, 2'-hydroxy taxol, 10-deacetyltaxol or 7-epi-taxol, and the plant alkaloids are selected from vincristine, vinblastine, vinorelbine, etc. The product can reduce toxic reaction, increase selectively drug concn., and enhance therapeutic effectiveness. .

Vinflunine: a new active drug for second-line treatment of advanced breast cancer

All Rights Reserved. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Campone, M.; Cortes-Funes, H.; Vorobiof, D.; Martin, M.; Slabber, C. F.; Ciruelos, E.; Bourbouloux, E.; Mendiola, C.; Delgado, F. M.; Colin, C.; Aslanis, V.; Fumoleau, P. (Centre Rene Gauducheau, Saint Herblain 44805, Fr.). British Journal of Cancer, 95(9), 1161-1166 (English) 2006 Nature Publishing Group. CODEN: BJCAAI. ISSN: 0007-0920. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin targeted agent vinflunine (VFL) (320 mg m-2 q 21 days) as second-line chemotherapy in patients with metastatic breast carcinoma (MBC). All patients had disease progression after anthracycline/taxane (A/T) therapy. They could have received a nonanthracycline adjuvant treatment and subsequently received a first-line A/T combination for advanced/metastatic disease; or relapsed >6 mo after completion of adjuvant A/T therapy and were subsequently treated with the alternative agent; or relapsed within 6 mo from an adjuvant A/T combination. Objective response was documented in 18 of 60 patients enrolled (RR: 30% (95% confidence interval (CI): 18.9-43.2%)). Among the responders, seven patients had relapsed during a period of <3 mo from taxane-based regimen yielding a RR of 33.3%. The median duration of response was 4.8 mo (95% CI: 4.2-7.2), median progression-free survival was 3.7 mo (95% CI: 2.8-4.2) and median overall survival was 14.3 mo (95% CI: 9.2-19.6). The most frequent adverse event was neutropenia (grade 3 in 28.3% and grade 4 in 36.7% of patients). No febrile neutropenia was obsd.In this experiment, several chemicals are used like 1605-68-1 and 162652-95-1 Fatigue (grade 3 in 16.7% of patients) and constipation (grade 3 in 11.7% of patients) were also common; these were non-cumulative and manageable permitting achievement of a good relative dose intensity of 93.5%. Vinflunine is an active agent with acceptable tolerance in the management of MBC patients previously treated with (A/T)-based regimens. These encouraging phase II results warrant further investigation of this novel agent in combination with other active agents in this setting or in earlier stages of disease. .